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Abstract 
Cardiotoxicity induced by anti-cancer therapeutics is a severe and potentially fatal adverse 
reaction of the heart in response to certain drugs.  Current in vitro approaches to assess 
cardiotoxicity have focused on analysing cardiomyocytes.  More recently it has become 
apparent that non-cardiomyocyte cells of the heart can potentially contribute to 
cardiotoxicity. Herceptin and doxorubicin are known to induce cardiotoxicity in the clinic. 
The effect of these drugs on the endothelial tight junction barrier was tested by analysing 
tight junction formation and zona occludens-1 (ZO-1) levels, revealing that Herceptin and 
doxorubicin are able to induce barrier perturbment and decrease barrier function in human 
cardiac microvascular endothelial cells (HCMECs) leading to increased permeabilty.  
Herceptin treatment had no effect on the tight junction barrier function in human dermal 
and human brain microvascular endothelial cells.  HCMECs showed detectable levels of 
HER2 compared with the other endothelial cells suggesting that Herceptin binding to 
HER2 in these cells may interfere with tight junction formation.  Our data suggests that 
doxorubicin and Herceptin can affect tight junction formation in the cardiac 
microvasculature leading to increased permeability and adverse effects on the cardiac 
myocytes. 
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Introduction 
 
Cardiotoxicity is defined as a severe and potentially fatal adverse cardiovascular event in 
response to certain drugs and is responsible for the majority of drug development 
terminations/withdrawals at the pre-clinical and post-approval stage over the last 10 years 
(Cross et al., 2015; Laverty et al., 2011). Drug induced cardiotoxicity can result in both 
functional effects such as arrhythmia and acute alteration of the contractile function 
(inotropy) of the heart, and morphological (structural) damage to the myocardium (Cross et 
al., 2015). 
 
The cardiac myocardium is composed of cardiomyocytes, which constitute approximately 
30% of the total cells, and non-myocytes (fibroblasts, endothelial cells), which constitute 
approximately 70% of the total cells (Brutsaert, 2003). Cardiomyocytes generate the 
contractile force while fibroblasts secrete extracellular matrix and paracrine factors (Porter 
and Turner, 2009; Ravenscroft et al., 2016). Endothelial cells line the coronary vasculature 
and form a barrier which regulates the movement of oxygen, free fatty acids and 
xenobiotics from the circulation (Brutsaert, 2003; Tirziu et al., 2010). Paracellular 
permeability is regulated by endothelial cell-cell junctions.  Adherens junctions initiate cell-
to-cell contacts and promote their maturation and maintenance while tight junctions 
regulate the passage of ions and solutes through the paracellular route (Bazzoni and 
Dejana, 2004; Gonzalez-Mariscal et al., 2005; Gonzalez-Mariscal et al., 2008). 
 
The anthracycline doxorubicin is used to treat a variety of cancers such as leukaemia, 
breast and ovarian cancer (Sartiano et al., 1979). Anthracyclines produce dose-related 
cardiac dysfunction, defined as type I cardiotoxicity (Ewer and Lippman, 2005), 
characterised by cardiomyocyte ultrastructural abnormalities, (vacuoles, myofibrillar 
disarray and necrosis), and contractile abnormalities (dilated cardiomyopathy) resulting in 
reduced left ventricular ejection fraction (LVEF) and heart failure (Billingham et al., 1978). 
Some elements are initially reversible, but over time the burden of fibrosis and myocyte 
loss to apoptosis renders the dysfunction irreversible. 
 
Herceptin (trastuzumab) is a humanised monoclonal antibody that specifically targets 
HER2 (EGFR-2/ERBB2) (Walshe et al., 2006), which is overexpressed in approximately 
20% of breast cancers (Baselga et al., 1998). Despite its clinical efficacy, Herceptin has 
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been demonstrated to lead to decreased LVEF in some patients and is classified as type II 
reversible cardiovascular toxicity (Lemmens et al., 2007; Sandoo et al., 2014).  The 
mechanism of cardiotoxicity has been attributed to blocking normal HER2 function in 
cardiomyocytes (Force et al., 2007). Gene ablation of Her2 in mice leads to embryonic 
lethality at day E9.5-10.5 due to trabeculae malformation in the heart (Harari and Yarden, 
2000).  HER2 can heterodimerise with HER3 (EGFR3) and HER4 (EGFR4) following 
agonist stimulation with neuregulins, which activates an intracellular signalling cascade in 
cardiomyocytes leading to cell survival (Creedon et al., 2014).  The importance of HER2 
function in cardiomyocytes is highlighted by the fact that cardiotoxicity of doxorubicin is 
aggravated by co-administration of Herceptin, which has led to the sequential 
administration of these drugs in patients to reduce the severity of cardiovascular toxicity 
(Gianni et al., 2007).  
 
Whilst the majority of studies analysing the molecular mechanism of cardiotoxicity have 
focused on effects on cardiomyocytes there is a growing awareness that cardiotoxic anti-
cancer drugs can also adversely affect cardiac vascular function (Chintalgattu et al., 2013; 
Chiusa et al., 2012). Tubulin binding drugs, such as vincristine, have been shown to 
adversely affect rat cardiac microvascular endothelial cells (Mikaelian et al., 2010) while 
doxorubicin has recently been shown to affect VEGF signalling in rat cardiac 
microvascular endothelial cells (Chiusa et al., 2012). We were interested in the possibility 
that cardiotoxic drugs such as Herceptin and doxorubicin may directly affect cardiac 
endothelial cell function. Using a number of in vitro methods we showed that doxorubicin 
and Herceptin can affect cardiac microvascular endothelial cell barrier function leading to 
increased drug permeability. This data suggests that cardiac microvascular injury may be 
an initiating and contributory event in drug-induced cardiotoxicity.  
 
. 
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Results 
 
Herceptin and doxorubicin affect tight junction formation and increase permeability 
in cardiac microvascular endothelial cells. 
 
In order for chemotherapy to be effective the drug must gain access to the tumour from the 
microvascular capillary bed. The tumour vasculature is relatively leaky due to aberrant 
angiogenesis allowing effective delivery of chemotherapy (Chung et al., 2010). In contrast, 
the blood-brain barrier (BBB) presents a relatively impermeable barrier to the delivery of 
chemotherapy such as doxorubicin and Herceptin to target brain metastasis (Deeken and 
Loscher, 2007).  We were interested in determining the effect of doxorubicin and Herceptin 
on microvascular permeability using human microvascular endothelial cells from different 
anatomical locations. We utilised human dermal microvascular endothelial cells (HDMECs), 
human cardiac microvascular endothelial cells (HCMECs) and human brain microvascular 
endothelial cells (HBMECs). 
 
The tight junction barrier was assessed by immunofluorescence staining of the tight 
junction protein zona occludens-1 (ZO-1).  The data presented in figures 1A-C 
demonstrate that doxorubicin induced tight junction barrier perturbment in HDMECs and 
HCMECs, but not HBMECs. This is in agreement with the fact that doxorubicin does not 
effectively penetrate the BBB in patients (Blasberg and Groothuis, 1986). Herceptin 
treatment caused tight junction barrier perturbment in HCMECs only.  This suggests that 
cardiac endothelial cells are more susceptible to Herceptin than endothelial cells from 
other anatomical locations. Analysis of the level of ZO-1 by Western blotting revealed that 
doxorubicin reduced the protein level in HDMECs and HCMECs. Herceptin had a slight 
effect in reducing ZO-1 levels in HDMECs but a profound effect in reducing ZO-1 levels in 
HCMECs, an effect augmented slightly by co-addition of doxorubicin (Fig.1D). Analysis of 
CD31 (PECAM-1), a transmembrane glycoprotein involved in cell adhesion and 
constitutively expressed on endothelial cells (Privratsky et al., 2011), revealed that drug 
treatment did not affect expression of this protein (Fig.1D). 
To assess the potential physiological relevance of drug-induced tight junction barrier 
perturbment, an in vitro assay was performed to measure permeability using FITC-labelled 
dextran.  Cells were treated with doxorubicin and Herceptin alone or in combination, 
before the flow of fluorescent dextran through the monolayer was measured (Fig.1E). This 
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data shows that doxorubicin significantly increased permeability in HDMECs and HCMECs 
but not in HBMECs. In agreement with effects on ZO-1, Herceptin increased permeability 
in only the HCMECs, an effect that was increased in the presence of doxorubicin. In order 
to preclude potential apoptotic effects with doxorubicin leading to barrier perturbment we 
analysed the level of cleaved caspase 3 following doxorubicin treatment.  Significant 
apoptosis was not observed in the HCMECs with 0.1 μM doxorubicin over a 24 hour time 
period (Fig.1F).   
 
Analysis of transporter expression and doxorubicin accumulation in different 
endothelial cells 
 
The ability of doxorubicin to affect permeability in HDMECs and HCMECs but not 
HBMECs suggests that endothelial cells in the BBB are resistant to the effect of 
doxorubicin, potentially due to decreased drug accumulation in these cells. We analysed 
the expression of different drug influx and efflux drug transporters across the range of 
endothelial cells.  Anti-cancer drugs such as doxorubicin are thought to be transported into 
cells by organic cation transporters (Koepsell et al., 2007). We analysed expression of two 
high affinity (OCTN1/SLC22A4, OCTN2/SLC22A5), as well as two low affinity 
(OCT1/SLC22A1, OCT2/SLC22A2) organic cation transporters. The HCMECs express 
relatively low levels of the high-affinity SLC22A4 and SLC22A5 transporters and relatively 
high levels of the low-affinity SLC22A1 and SLC22A2 transporters compared to the 
HBMECs and A2780 ovarian carcinoma cells (Fig.2A). 
 
The drug efflux pump P-glycoprotein (P-gp, ABCB1/MDR-1) has been demonstrated to be 
involved in doxorubicin removal from cells (Sardi et al., 2013; Zhang et al., 2014) and has 
been shown to be expressed at high levels within the blood brain barrier (BBB) (Billson et 
al., 1994).  HBMECs expressed relatively high levels of P-gp compared to the other 
endothelial cells (Fig.2B) confirming their primary phenotype. Doxorubicin is intrinsically 
fluorescent (Karukstis et al., 1998),  which allows for drug uptake and accumulation in cells 
to be monitored. We measured doxorubicin uptake over time both visually to determine 
intracellular localisation and quantitatively to determine how uptake varies between cell 
types.  The data in figure 3A demonstrates that doxorubicin was taken up into HCMECs 
and accumulated in the nucleus over time.  To assess the difference in accumulation 
within the different endothelial cells the fluorescence within the cells relative to the protein 
concentration was measured.  A2780 cells showed the highest accumulation of 
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doxorubicin over time; doxorubicin levels in all of the different endothelial cells were very 
similar (Fig.3B).  Taken together, this suggests that the differential effects of doxorubicin 
on tight junctions in HCMECs and HDMECs, compared with HBMECs, cannot be 
explained by potentially increased accumulation of doxorubicin in these cells. 
 
 
Analysis of molecular mechanism of Herceptin action on HCMECs. 
 
Herceptin is known to target HER2 and inhibit the receptors ability to heterodimerise with 
HER3 and HER4 preventing activation and increasing endocytosis of HER2 (Yarden, 
2001). Following the observation that Herceptin reduces tight junction formation and 
increases permeability in HCMECs, we investigated the expression of HER2 and HER4 in 
different endothelial cell types.  We analysed a number of different batches of endothelial 
cells from different donors. We also utilised A2780 ovarian cancer cells, which are known 
to express HER2.  Analysis of the expression levels of the EGFR family members EGFR1, 
HER2, HER3 and HER4 by qRT-PCR revealed that HCMECs express detectable levels of 
EGFR-1 mRNA and HER2 mRNA compared to other endothelial cells (Fig. 4A). This level 
of expression was considerably lower than the level expressed in the A2780 ovarian 
tumour cells. To confirm our findings, we analysed the expression of the HER2 protein by 
immunofluorescence, which revealed detectable levels of HER2 protein on the surface of 
the HCMECs relative to other endothelial cells (Fig.4B).  
 
The expression of HER2 on HCMECs may have a functional significance with respect to 
activation of intracellular signalling pathways.  There is no known ligand for HER2, but the 
receptor is known to dimerise with HER3 and HER4.  We used the ligand neuregulin-1 
(NRG-1), which is known to bind and activate HER4 (Lemmens et al., 2006; Yarden, 2001). 
Stimulation with NRG-1 failed to evoke activation of HER2 and downstream activation of 
AKT and ERK1/2 in all endothelial cells (Fig.5A). In contrast, VEGF-A, which binds to the 
VEGFR-2 present on endothelial cells (Holmes et al., 2007) was able to stimulate AKT 
phosphorylation and ERK1/2 phosphorylation in all endothelial cells. NRG-1 was able to 
stimulate HER2 phosphorylation in the A2780 ovarian cancer cells, in agreement with the 
expression of HER3 and HER4 mRNA in these cells (Fig.5A). Analysis of cell proliferation 
following ligand stimulation confirmed that whilst endothelial cells responded to VEGF-A, 
they did not respond to NRG-1.  In contrast, NRG-1 was able to evoke a proliferative 
response in the A2780 cells (Fig.5B). Taken together, these data suggest that whilst 
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HCMECs express detectable levels of EGFR-1 and HER2, the lack of detectable levels of 
HER4 prevents dimerisation and ligand induced activation of HER2, and concomitant 
activation of downstream signalling pathways. 
 
Analysis of effect of doxorubicin and Herceptin on cell viability. 
 
Herceptin is known to bind to HER2 expressed on breast and ovarian cancer cells causing 
cytotoxicity in vivo by inhibiting HER2 mediated intracellular signalling, increasing HER2 
endocyotsis and  stimulating antibody-directed cell cytotoxicity (ADCC) (Collins et al., 
2012; Kute et al., 2012; Yoshida et al., 2012).  Addition of Herceptin alone caused a 
reduction in cell viability in the A2780 cells (Fig. 6A) with an IC50 of 2.6 μM; endothelial 
cells were not as sensitive to Herceptin with IC50s of approximately 30 μM. We were 
interested in determining the effect of co-addition of doxorubicin and Herceptin on cell 
viability in vitro.  Addition of Herceptin caused a reduction in cell viability in the presence of 
doxorubicin, compared to doxorubicin alone, in the A2780 cells (Fig. 6F), with no 
enhancement of doxorubicin toxicity evident in the endothelial cells (Fig. 6 C-E).  
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Discussion  
 
Cardiotoxicity is a problem with current chemotherapy and has previously been thought to 
relate to adverse effects on cardiomyocytes (Adamcova et al., 2007; Lemmens et al., 
2006). However, there is a growing awareness that non-cardiomyocyte cells such as 
endothelial cells can be adversely affected by cancer therapy (Wolf and Baynes, 2006). 
Our data shows that doxorubicin and Herceptin can increase cardiac microvascular 
endothelial cell permeability resulting in increased paracellular permeability. In patients, 
this would potentially lead to exposure of cardiomyocytes to doxorubicin and Herceptin 
leading to adverse effects of the drugs. 
 
Anthracycline induced cardiotoxicity has traditionally focused on effects on cardiac 
myocytes that lead to contractile dysfunction. Recent data has shown that doxorubicin can 
affect endothelial cells leading to increased intracellular redox stress (Wojcik et al., 2014) 
and apoptosis (Takemura and Fujiwara, 2007).  Our data shows that doxorubicin can 
affect cardiac and dermal microvascular endothelial cell barrier function leading to loss of 
ZO-1 in tight junctions and an increase in paracellular permeability (Fig.1 A-E).  This effect 
was evident after 3-6 h and occurred in the absence of apoptosis, suggesting that it is not 
a consequence of programmed cell death. The inability of doxorubicin to affect brain 
microvascular endothelial cell tight junction formation and permeability was in agreement 
with the fact that in vivo doxorubicin does not cross the BBB, precluding its use in the 
treatment of brain malignancies (Deeken and Loscher, 2007). 
 
Doxorubicin is thought to be transported into cells by the organic cation transporters (OCT).  
Interestingly, the HCMECs expressed relatively high levels of the recently identified high 
affinity doxorubicin transporter OCT1/SLC22A1 (Andreev et al., 2016). However, the 
differential effects of doxorubicin on the endothelial cells were not due to differences in 
drug accumulation as doxorubicin accumulated to similar levels over 8hrs in all endothelial 
cells, with higher levels evident in the A2780 ovarian carcinoma cells. 
 
The ability of doxorubicin to affect cardiac microvascular endothelial cell permeability in 
vivo has been reported in rat studies where cardiac permeability changes correlated with 
decreased left ventricular function (Fernandez-Fernandez et al., 2014).  Taken together, 
our data suggests that doxorubicin can interfere with tight junction formation between 
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cardiac microvascular endothelial cells leading to increased permeability to the drug and 
ultimately detrimental effects on the underlying myocardium.   
 
Anthracyclines are often utilised with Herceptin in drug treatment regimens for breast and 
ovarian cancers overexpressing HER2 (Pegram et al., 1999).  Concurrent treatment with 
these drugs leads to increased cardiotoxicity through significantly decreased LVEF which 
has led to the sequential use of these drugs in an attempt to minimise cardiotoxicity.  The 
ability of Herceptin to adversely affect cardiac function has been attributed to binding to 
HER2 receptors on cardiomyocytes leading to “on-target” toxicity. The importance of 
HER2 in heart development has been linked to expression of the receptor in myocytes 
(Harari and Yarden, 2000).  Endothelial cells are known to secrete neuregulins which can 
stimulate EGFRs on myocytes in a paracrine manner (Lemmens et al., 2006) regulating 
heart development (Lee et al., 1995).  The reduced formation of the ventricular myocardial 
trabecular in Her2 null mice produces a lethal phenotype at E9.5/10.5 (Harari and Yarden, 
2000).  During morphogenesis of the heart the myocardial trabecular functions to supply a 
blood flow. The reduced formation of the myocardial trabecular consequently results in 
reduced blood flow, which is considered a probable explanation for lethality in Her2 null 
mice (Lee et al., 1995).  Even though the reduced blood flow could be due to endothelial 
defects, HER2 function has not currently, to our knowledge, been investigated for its role 
in endothelial cell function.  
 
Our data shows that Herceptin is able to reduce cardiac microvascular tight junction 
formation resulting in a concomitant increase in permeability (Fig.1B & D), an effect not 
observed in the other endothelial cells. This effect was also increased in the presence of 
doxorubicin suggesting that cardiac microvascular endothelial barrier formation was 
uniquely sensitive to a combination of both drugs.  Analysis of the expression levels of 
EGFR family members revealed that HCMECs express significantly higher levels of 
EGFR-1, HER2 and HER4 than dermal or brain microvascular endothelial cells. However, 
the HER2 did not appear to be functional as neuregulin did not evoke HER2 
phosphorylation and a subsequent intracellular signalling response (Fig. 5A) and 
proliferation (Fig.5B) in the HCMECs in contrast to the A2780 ovarian cancer cells (Fig. 
5A-C).  This is most probably due to the fact that expression of HER2 and HER3 in the 
HCMECs is an order of magnitude lower than in the A2780 cells preventing receptor 
dimerization in the presence of the NRG-1 ligand (Fig. 4).  However, whilst the HER2 
expression in HCMECs was not high enough to facilitate a NRG-1 response, it was high 
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enough to be detected by immunofluorescence with an anti-HER2 antibody.  This data 
suggests that Herceptin can bind to HER2 on the surface of HCMECs and potentially 
interfere with tight junction formation. A link between HER2 and ZO-1 has been defined in 
endometrial Ishikawa cells, where downregulation of HER2 led to arecoline induced 
alterations in tight junctions (Giri et al., 2010).   
 
Herceptin binding to HER2 in vivo is able to prevent cancer cell proliferation by  three 
defined pathways: inhibition of intracellular signalling, sequestration of the immune system 
and receptor internalisation (Kute et al., 2009).  Analysis of Herceptin effects on cell 
viability revealed that the endothelial cells were relatively insensitive to this drug compared 
with the A2780 cells (Fig.6 A-B). Furthermore, an additive effect on cell viability of co-
addition of Herceptin and doxorubicin compared with doxorubicin alone was only evident 
in the A2780 cells confirming the relative insensitivity of endothelial cells to effects on cell 
viability with Herceptin. 
 
Our data shows that the cardiotoxic drugs doxorubicin and Herceptin can both affect 
cardiac microvascular endothelial cell barrier function leading to increased permeability. 
This suggests that the cardiotoxicity observed in vivo with these agents may be due to 
multi-cellular effects with adverse effects on the cardiac endothelium a potentially initiating 
and contributory event in drug-induced cardiotoxicity. 
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Materials and Methods 
 
Cell culture 
 
Human dermal microvascular endothelial cells (HDMECs, #C-12212, lot-0092101.2 and 
6060707.1, human cardiac microvascular endothelial cells (HCMECs, #C12285, lot-
3011401, 9090701.2 and 1122702) and human brain microvascular endothelial cells 
(HBMECs, #C-12287, lot-1111603.7) were purchased from PromoCell (Heidelberg, 
Germany).  Endothelial cells were routinely cultured on 0.5% (w/v) gelatin-coated cell 
culture dishes (G1890) Sigma, Poole, UK) at passages 2-10.  Endothelial cells were 
cultured in endothelial basal MV2 medium (EBM) supplemented with 5% v/v fetal calf 
serum (FCS), recombinant epidermal growth factor (EGF, 5 ng/ml), recombinant human 
basic fibroblast growth factor (FGF, 10 ng/ml), long R3 insulin-like growth factor (IGF, 20 
ng/ml), recombinant human vascular endothelial growth factor-A165 (VEGF-A, 0.5 ng/ml), 
ascorbic acid (1 µg/ml) and hydrocortisone (0.2 µg/ml), referred to herein as endothelial 
full growth-medium (FGM).  A2780 were routinely cultured in RPMI 1640 medium 
(#61870044 Gibco) supplemented with 10% v/v FCS.  All cells were incubated at 37ºC in 
humidified air containing 5% (v/v) CO2.   
 
Cell stimulation and preparation of cell lysates 
 
Before stimulation with agonists, cells were serum-starved for 20 h in EBM supplemented 
with 1% v/v FCS for HDMECs, HCMECs and HBMECs or RPMI 1640 supplemented with 
1% FCS for A2780.  Cells were stimulated with 50 ng/ml agonists (VEGF-A, NRG-1; 
Peprotech, Rocky Hill, NJ) for 10 minutes.  For preparation of total cell lysates, cells were 
maintained in endothelial FGM.  Cells were washed in ice-cold Dulbecco’s phosphate-
buffered saline (DPBS, Lonza, Basel, Switzerland) and lysed on ice in modified RIPA 
buffer (20 mM Tris pH 7.5, 150 mM NaCl, 2.5 mM EDTA, 10% w/v glycerol, 1% v/v Triton 
X-100, 1 mM Na3VO4, 10 µg/ml aprotinin, leupeptin and pepstatin A, 1 mM PMSF, 0.5% 
v/v S.D.S and 0.5% v/v sodium deoxycholate). Lysates were centrifuged (14,000 RPM for 
20 minutes at 4ºC) before diluting in LDS sample buffer (Invitrogen, Paisley, UK) 
containing 2.5% (v/v) 2-mercaptoethanol (Sigma, Poole, UK) and denaturing at 90ºC for 6 
minutes.   
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Western blot analysis 
 
Proteins were resolved by S.D.S-PAGE on 10% tris-glycine gels and transferred to 0.2 µm 
nitrocellulose membrane (Hybond-C, GE Healthcare, Amersham, UK).  Membranes were 
then blocked in 5% w/v bovine serum albumin (BSA) in Tris-buffered saline (TBS) with 
0.1% v/v Tween-20 (TBST).  Membranes were probed overnight with primary antibodies 
diluted in 2% w/v BSA in TBST, directed against: phosphorylated AKT (Ser473), 
phosphorylated ERK1/2 (Thr202/Tyr204), glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH), caspase 3, cleaved caspase 3 (Asp175), HER2 and HER4 (New England 
Biolabs, Hitchin, UK) and P-glycoprotein (P-gp, Abcam).  Antibody to ZO-1 (#61-7300) was 
purchased from Invitrogen (Thermo Fisher Scientific) and CD31 (#M082329-2) purchased 
from Dako (Denmark).  Proteins were detected by using rabbit- or mouse-specific HRP 
secondary antibodies (Jackson Labs) and enhanced-chemiluminescence (ECL) Western 
blotting detection reagent (Pierce).   
 
 
Quantitative real-time PCR (qRT-PCR) analysis  
 
Total RNA was extracted from cells using the RNAeasy kit following the manufacturer’s 
instructions (Qiagen, Crawley, UK).  Synthesis of cDNA was conducted by reverse 
transcription using 1 µg total RNA, oligo dT18, RNase OUT, M-MLV Reverse Transcriptase 
(Invitrogen, Thermo Fisher Scientific).  Mixtures used for qRT-PCR included: 1.5 µl cDNA, 
3 µl dH2O (RNase and DNase free), 12.5 µl 2X Power SYBR® Green mastermix (Applied 
Biosystems, Warrington, UK) and 0.25 µM forward and reverse primers (Invitrogen).  
Primers: EGFR1 forward 5’ TAT GTT CCC TCC AGG TCA GC 3’; EGFR1 reverse 5’ GCA 
CCT GTA AAA TGC CCT GT 3’; HER2 forward 5’ CTA CGG CAG AGA ACC CAG AG 3’; 
HER2 reverse 5’ CTT GAT GCC AGC AGA AGT CA 3’; HER3 forward 5’ CTT ATC CGA 
GGG CAA ATT CA 3’; HER3 reverse 5’ TTT CCC TTA GTT CCC CAT CC 3’; HER4 
forward 5’ TGT GTT CCA GTG ATG GCT GT 3’; HER4 reverse 5’ CCA TTC TCA AAC 
TCC CGA AA 3’; P-gp forward 5’ GTG GGG CAA GTC AGT TCA TT 3’; P-gp reverse 5’ 
TTC CAA TGT GTT CGG CAT TA 3’; ABCC1 forward 5’ GCC GGT GAA GGT TGT GTA 
CT 3’; ABCC1 reverse 5’ AGG GGT TCC ACT CCT TCT GT 3’; ABCC4 forward 5’ GGC 
GAA TTG TTA GCT GTG GT 3’; ABCC4 reverse 5’ CAG GGC TGC TGA GAC ACA TA 3’; 
SLC22A5 forward 5’ CTG GTG GTT CAT CCC TGA GT 3’; SLC22A5 reverse 5’ AGT 
GGA AGG CAC AAC AAT CC 3’; SLC22A2 forward 5’ TCG CTT AAT CCA AGG ACT GG 
14 
 
3’; SLC22A2 reverse 5’ CAC CAG GAG CCC AAC TGT AT 3’; SLC22A4 forward 5’ CTG 
CCC AGG CGT TAT ATC AT 3’; SLC22A4 reverse 5’ AAT TTT CCC AGC ATG ACC AG 
3’.  qRT-PCR reactions were performed on a ViiA7 Real-Time PCR system (Applied 
Biosystems, Foster City, CA) using the parameters: 50ºC for 2 minutes and 95ºC for 10 
minutes followed by 95ºC for 15 seconds and 60ºC for 1 minute, repeating for 40 cycles.  
Cycle threshold (CT) values were obtained for the mRNA of interest to compare to the 
GAPDH control to determine gene expression changes using the Comparative CT (2-ΔΔCT) 
method (Livak and Schmittgen, 2001).  
 
Doxorubicin and Herceptin treatment of cells 
 
HDMECs, HCMECs and HBMECs were plated on gelatin-coated 13mm glass coverslips 
and placed in the well of a 24-well plate and allowed to reach confluence over a 7 day 
period with media changes every 2-3 days.  Cells were treated with doxorubicin 
(purchased from Sigma, 30mM stock in DMSO) diluted to 0.1 µM in endothelial FGM to 
ensure final 0.1% v/v DMSO concentration.  Herceptin (purchased from Clatterbridge 
Hospital Pharmacy, 100 mg/ml stock in PBS) was used at 10 µg/ml diluted in endothelial 
FGM.  Control human IgG (#31154) was purchased from Invitrogen (Thermo Fisher 
Scientific). Drugs were added to the cells individually or in combination for 6 hours.   
 
Immunofluorescence 
 
HDMECs, HCMECs, HBMECs and A2780 grown on glass coverslips were fixed in 2% w/v 
paraformaldehyde (PFA), permeabilised in 0.25% (v/v) Triton X-100, blocked in 1% BSA in 
TBST with 5% v/v donkey serum for 1 hour.  Cells were incubated in primary antibodies for 
1 hour: HER2 and HER4 (New England Biolabs, Hitchin, UK) and ZO-1 (ThermoFisher).  
Cells were washed and incubated with Alexa Fluor® secondary antibodies donkey-anti-
rabbit IgG (H+L) 488 (Invitrogen, Thermo Fisher Scientific) for 1 hour.  Additional to ZO-1 
cells were stained with Alexa Fluor® Phalloidin 568 incubated additional to secondary 
antibody.  Nuclei were labelled with 10 μg/ml Hoechst 33342 (Invitrogen, Thermo Fisher 
Scientific) for 10 minutes.  Coverslips were mounted using Prolong Gold mounting medium 
(Invitrogen, Thermo Fisher Scientific) and visualised on a Zeiss AxioObserver Z1 inverted 
fluorescence microscope with Apotome2 optical sectioning device. 
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Permeability 
 
HDMECs, HCMECs and HBMECs were grown to confluence over 7 days on ThinCerts™ 
0.4 µm translucent (Greiner).  Cells were treated with drugs for 6 h before washing the 
inserts in DPBS and addition of 4 kDa FITC fluorescent dextran (Sigma) diluted in phenol 
red free endothelial FGM for 25 minutes.  The flow through was measured by taking a 
sample of medium from the surrounding well and measuring the level of fluorescence 
(Varioskan plate reader at Ex 490 nm and Em 525 nm).    
 
Cell viability 
 
HDMECs, HCMECs, HBMECs and A2780 were grown to sub-confluence in gelatin-coated 
24-well plates before being treated with doxorubicin (100µM – 0.03µM) alone or in 
combination with Herceptin 10 µg/ml or IgG control 10 µg/ml for 72 hours.  Cells were 
lysed in Cell Titer Glo (Promega) and the contents transferred to white 96-well flat 
bottomed plates and the bioluminescence measured (Varioskan plate reader).    
 
Statistical significance 
 
This was performed using a one-way analysis of variance (ANOVA) followed by Dunnett’s 
post-hoc test using SPSS software. Significant differences between control and test 
groups were evaluated with P values less than 0.05 (*), indicated on the graphs. Error bars 
in graphs and histograms denote ±S.D. (standard deviation). 
 
 
16 
 
Acknowledgements 
This work was supported by a MRC in vivo capacity building studentship to E.L.W. 
 
Conflict of Interest 
The authors declare no conflict of interest. 
 
Author contributions 
E.L.W. designed and performed experiments, analysis and interpretation of data and co-
wrote the paper. J.E.S. and M.J.C. conception and design, analysis and interpretation of 
data and co-wrote the paper. 
 
  
17 
 
References 
 
 Adamcova, M., Simunek, T., Kaiserova, H., Popelova, O., Sterba, M., Potacova, A., 
Vavrova, J., Malakova, J. and Gersl, V. (2007). In vitro and in vivo examination of cardiac 
troponins as biochemical markers of drug-induced cardiotoxicity. Toxicology 237, 218-28. 
 Andreev, E., Brosseau, N., Carmona, E., Mes-Masson, A. M. and Ramotar, D. (2016). 
The human organic cation transporter OCT1 mediates high affinity uptake of the anticancer 
drug daunorubicin. Sci Rep 6, 20508. 
 Baselga, J., Norton, L., Albanell, J., Kim, Y. M. and Mendelsohn, J. (1998). 
Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of 
paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. 
Cancer Res 58, 2825-31. 
 Bazzoni, G. and Dejana, E. (2004). Endothelial cell-to-cell junctions: molecular 
organization and role in vascular homeostasis. Physiol Rev 84, 869-901. 
 Billingham, M. E., Mason, J. W., Bristow, M. R. and Daniels, J. R. (1978). 
Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep 62, 865-
72. 
 Billson, A. L., Palmer, J. B., Walker, D. A. and Lowe, J. (1994). Multidrug resistance 
gene (MDR 1) expression in neuro-axial tumours of children and young adults. Br J Neurosurg 
8, 585-91. 
 Blasberg, R. G. and Groothuis, D. R. (1986). Chemotherapy of brain tumors: 
physiological and pharmacokinetic considerations. Semin Oncol 13, 70-82. 
 Brutsaert, D. L. (2003). Cardiac endothelial-myocardial signaling: its role in cardiac 
growth, contractile performance, and rhythmicity. Physiol Rev 83, 59-115. 
 Chintalgattu, V., Rees, M. L., Culver, J. C., Goel, A., Jiffar, T., Zhang, J., Dunner, K., Jr., 
Pati, S., Bankson, J. A., Pasqualini, R. et al. (2013). Coronary microvascular pericytes are the 
cellular target of sunitinib malate-induced cardiotoxicity. Sci Transl Med 5, 187ra69. 
 Chiusa, M., Hool, S. L., Truetsch, P., Djafarzadeh, S., Jakob, S. M., Seifriz, F., Scherer, 
S. J., Suter, T. M., Zuppinger, C. and Zbinden, S. (2012). Cancer therapy modulates VEGF 
signaling and viability in adult rat cardiac microvascular endothelial cells and cardiomyocytes. 
J Mol Cell Cardiol 52, 1164-75. 
 Chung, A. S., Lee, J. and Ferrara, N. (2010). Targeting the tumour vasculature: 
insights from physiological angiogenesis. Nat Rev Cancer 10, 505-14. 
 Collins, D. M., O'Donovan, N., McGowan, P. M., O'Sullivan, F., Duffy, M. J. and Crown, 
J. (2012). Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in 
HER-2-non-amplified breast cancer cell lines. Ann Oncol 23, 1788-95. 
 Creedon, H., Byron, A., Main, J., Hayward, L., Klinowska, T. and Brunton, V. G. 
(2014). Exploring mechanisms of acquired resistance to HER2 (human epidermal growth 
factor receptor 2)-targeted therapies in breast cancer. Biochemical Society Transactions 42, 
822-830. 
 Cross, M. J., Berridge, B. R., Clements, P. J., Cove-Smith, L., Force, T. L., Hoffmann, 
P., Holbrook, M., Lyon, A. R., Mellor, H. R., Norris, A. A. et al. (2015). Physiological, 
pharmacological and toxicological considerations of drug-induced structural cardiac injury. Br 
J Pharmacol 172, 957-74. 
 Deeken, J. F. and Loscher, W. (2007). The blood-brain barrier and cancer: 
transporters, treatment, and Trojan horses. Clin Cancer Res 13, 1663-74. 
 Ewer, M. S. and Lippman, S. M. (2005). Type II chemotherapy-related cardiac 
dysfunction: time to recognize a new entity. J Clin Oncol 23, 2900-2. 
18 
 
 Fernandez-Fernandez, A., Carvajal, D. A., Lei, T. and McGoron, A. J. (2014). 
Chemotherapy-Induced Changes in Cardiac Capillary Permeability Measured by Fluorescent 
Multiple Indicator Dilution. Annals of Biomedical Engineering 42, 2405-2415. 
 Force, T., Krause, D. S. and Van Etten, R. A. (2007). Molecular mechanisms of 
cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 7, 332-44. 
 Gianni, L., Salvatorelli, E. and Minotti, G. (2007). Anthracycline cardiotoxicity in 
breast cancer patients: synergism with trastuzumab and taxanes. Cardiovasc Toxicol 7, 67-71. 
 Giri, S., Poindexter, K. M., Sundar, S. N. and Firestone, G. L. (2010). Arecoline 
induced disruption of expression and localization of the tight junctional protein ZO-1 is 
dependent on the HER 2 expression in human endometrial Ishikawa cells. BMC Cell Biol 11, 53. 
 Gonzalez-Mariscal, L., Nava, P. and Hernandez, S. (2005). Critical role of tight 
junctions in drug delivery across epithelial and endothelial cell layers. J Membr Biol 207, 55-
68. 
 Gonzalez-Mariscal, L., Tapia, R. and Chamorro, D. (2008). Crosstalk of tight junction 
components with signaling pathways. Biochim Biophys Acta 1778, 729-56. 
 Harari, D. and Yarden, Y. (2000). Molecular mechanisms underlying ErbB2/HER2 
action in breast cancer. Oncogene 19, 6102-6114. 
 Holmes, K., Roberts, O. L., Thomas, A. M. and Cross, M. J. (2007). Vascular 
endothelial growth factor receptor-2: structure, function, intracellular signalling and 
therapeutic inhibition. Cell Signal 19, 2003-12. 
 Karukstis, K. K., Thompson, E. H., Whiles, J. A. and Rosenfeld, R. J. (1998). 
Deciphering the fluorescence signature of daunomycin and doxorubicin. Biophys Chem 73, 
249-63. 
 Koepsell, H., Lips, K. and Volk, C. (2007). Polyspecific organic cation transporters: 
structure, function, physiological roles, and biopharmaceutical implications. Pharm Res 24, 
1227-51. 
 Kute, T., Stehle Jr, J. R., Ornelles, D., Walker, N., Delbono, O. and Vaughn, J. P. 
(2012). Understanding key assay parameters that affect measurements of trastuzumab-
mediated ADCC against Her2 positive breast cancer cells. Oncoimmunology 1, 810-821. 
 Kute, T. E., Savage, L., Stehle, J. R., Jr., Kim-Shapiro, J. W., Blanks, M. J., Wood, J. and 
Vaughn, J. P. (2009). Breast tumor cells isolated from in vitro resistance to trastuzumab 
remain sensitive to trastuzumab anti-tumor effects in vivo and to ADCC killing. Cancer 
Immunol Immunother 58, 1887-96. 
 Laverty, H., Benson, C., Cartwright, E., Cross, M., Garland, C., Hammond, T., 
Holloway, C., McMahon, N., Milligan, J., Park, B. et al. (2011). How can we improve our 
understanding of cardiovascular safety liabilities to develop safer medicines? Br J Pharmacol 
163, 675-93. 
 Lee, K. F., Simon, H., Chen, H., Bates, B., Hung, M. C. and Hauser, C. (1995). 
Requirement for Neuregulin Receptor Erbb2 in Neural and Cardiac Development. Nature 378, 
394-398. 
 Lemmens, K., Doggen, K. and De Keulenaer, G. W. (2007). Role of neuregulin-
1/ErbB signaling in cardiovascular physiology and disease: implications for therapy of heart 
failure. Circulation 116, 954-60. 
 Lemmens, K., Segers, V. F., Demolder, M. and De Keulenaer, G. W. (2006). Role of 
neuregulin-1/ErbB2 signaling in endothelium-cardiomyocyte cross-talk. J Biol Chem 281, 
19469-77. 
 Livak, K. J. and Schmittgen, T. D. (2001). Analysis of relative gene expression data 
using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402-8. 
 Mikaelian, I., Buness, A., de Vera-Mudry, M. C., Kanwal, C., Coluccio, D., Rasmussen, 
E., Char, H. W., Carvajal, V., Hilton, H., Funk, J. et al. (2010). Primary endothelial damage is 
the mechanism of cardiotoxicity of tubulin-binding drugs. Toxicol Sci 117, 144-51. 
19 
 
 Pegram, M., Hsu, S., Lewis, G., Pietras, R., Beryt, M., Sliwkowski, M., Coombs, D., 
Baly, D., Kabbinavar, F. and Slamon, D. (1999). Inhibitory effects of combinations of HER-
2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. 
Oncogene 18, 2241-51. 
 Porter, K. E. and Turner, N. A. (2009). Cardiac fibroblasts: at the heart of myocardial 
remodeling. Pharmacol Ther 123, 255-78. 
 Privratsky, J. R., Paddock, C. M., Florey, O., Newman, D. K., Muller, W. A. and 
Newman, P. J. (2011). Relative contribution of PECAM-1 adhesion and signaling to the 
maintenance of vascular integrity. J Cell Sci 124, 1477-85. 
 Ravenscroft, S. M., Pointon, A., Williams, A. W., Cross, M. J. and Sidaway, J. E. 
(2016). Cardiac Non-myocyte Cells Show Enhanced Pharmacological Function Suggestive of 
Contractile Maturity in Stem Cell Derived Cardiomyocyte Microtissues. Toxicol Sci 152, 99-
112. 
 Sandoo, A., Kitas, G. D. and Carmichael, A. R. (2014). Endothelial dysfunction as a 
determinant of trastuzumab-mediated cardiotoxicity in patients with breast cancer. 
Anticancer Res 34, 1147-51. 
 Sardi, I., la Marca, G., Cardellicchio, S., Giunti, L., Malvagia, S., Genitori, L., 
Massimino, M., de Martino, M. and Giovannini, M. G. (2013). Pharmacological modulation 
of blood-brain barrier increases permeability of doxorubicin into the rat brain. Am J Cancer 
Res 3, 424-32. 
 Sartiano, G. P., Lynch, W. E. and Bullington, W. D. (1979). Mechanism of action of the 
anthracycline anti-tumor antibiotics, doxorubicin, daunomycin and rubidazone: preferential 
inhibition of DNA polymerase alpha. J Antibiot (Tokyo) 32, 1038-45. 
 Takemura, G. and Fujiwara, H. (2007). Doxorubicin-induced cardiomyopathy from 
the cardiotoxic mechanisms to management. Prog Cardiovasc Dis 49, 330-52. 
 Tirziu, D., Giordano, F. J. and Simons, M. (2010). Cell communications in the heart. 
Circulation 122, 928-37. 
 Walshe, J. M., Denduluri, N., Berman, A. W., Rosing, D. R. and Swain, S. M. (2006). A 
phase II trial with trastuzumab and pertuzumab in patients with HER2-overexpressed locally 
advanced and metastatic breast cancer. Clin Breast Cancer 6, 535-9. 
 Wojcik, T., Buczek, E., Majzner, K., Kolodziejczyk, A., Miszczyk, J., Kwiatek, W., 
Baranska, M., Szymonski, M. and Chlopicki, S. (2014). Comparative endothelial profiling of 
doxorubicin and daunorubicin in cultured endothelial cells. Toxicol In Vitro. 
 Wolf, M. B. and Baynes, J. W. (2006). The anti-cancer drug, doxorubicin, causes 
oxidant stress-induced endothelial dysfunction. Biochim Biophys Acta 1760, 267-71. 
 Yarden, Y. (2001). The EGFR family and its ligands in human cancer. signalling 
mechanisms and therapeutic opportunities. Eur J Cancer 37 Suppl 4, S3-8. 
 Yoshida, R., Tazawa, H., Hashimoto, Y., Yano, S., Onishi, T., Sasaki, T., Shirakawa, 
Y., Kishimoto, H., Uno, F., Nishizaki, M. et al. (2012). Mechanism of resistance to 
trastuzumab and molecular sensitization via ADCC activation by exogenous expression of 
HER2-extracellular domain in human cancer cells. Cancer Immunol Immunother 61, 1905-16. 
 Zhang, J., Sun, T., Liang, L., Wu, T. and Wang, Q. (2014). Drug promiscuity of P-
glycoprotein and its mechanism of interaction with paclitaxel and doxorubicin. Soft Matter 10, 
438-45. 
 
 
 
  
20 
 
Figure Legends. 
Fig.1.  Effects on the tight junction barrier and permeability following doxorubicin 
and Herceptin treatment.  Immunofluorescence imaging of endothelial tight junctions 
(ZO-1, green), actin stress fibers (phalloidin, red) and nuclei (Hoechst, blue) following 
treatment with doxorubicin 0.1 µM and/or Herceptin 10 µg/ml for 6 h. (A) HDMECs, (B) 
HCMECs and (C) HBMECs; arrows indicate barrier perturbment.  Scale bar represents 
10μm. Results are from 1 experiment representative of 3. (D) Western blot of ZO-1, CD31 
(PECAM-1) and GAPDH levels in HDMECs, HCMECs and HBMECs following treatment 
with doxorubicin 0.1 µM and/or Herceptin 10 µg/ml for 6 h. Level of ZO-1 is quantified 
relative to vehicle control level for each cell type. (E) Permeability of 4kDa dextran-FITC 
through an endothelial monolayer on inserts, (n=4), mean ± S.D., * = p ≤ 0.05 compared to 
vehicle control, one way ANOVA, SPSS. (F) Western blotting analysis of cleaved caspase-
3 in HCMEC treated with 0.1 μM doxorubicin for different time periods.   Staurosporine (50 
nM) was added for 6 h as a positive control for apoptosis. 
 
Fig. 2.  Expression levels of drug influx and efflux transporters in different human 
cell lines.  Total RNA was isolated from HDMEC #1, HDMEC #2, HCMEC #1, HCMEC #2, 
HBMEC and A2780 cells and mRNA levels analysed by qRT-PCR for expression of: (A) 
organic cation influx transporters, (B) drug efflux  transporters.  (n=3), mean ± S.D..     
 
Fig. 3. Doxorubicin uptake and accumulation in cells.  (A) HCMEC were treated with  
1μM doxorubicin for time periods from 5 minutes to 6 hours, cells were stained with 
Hoechst to visualise nuclei.  Doxorubicin intrinsic fluorescence is detected at 568nm, 
appearing in red.  (B) Quantification of the levels of doxorubicin in HDMEC, HCMEC, 
HBMEC and A2780 over time relative to protein concentration. Scale bar represents 10 
μm. 
 
Fig. 4.  Expression of EGF receptors in different human cell lines.  (A) Total RNA was 
extracted from cells and mRNA levels of VEGFR-2, EGFR-1, HER2, HER3 and HER4 
analysed by qRT-PCR, compared to HDMEC #1, mean ± S.D., (n=3), * = p ≤ 0.05, one 
way ANOVA, SPSS. (B) Immunofluorescence analysis of HER2 and HER4 levels (green) 
in HDMECs, HCMECs, HBMECs and A2780.  Nuclei were visualised with Hoechst 
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staining (blue). Scale bar represents 10μm. Results are from 1 experiment representative 
of 3. 
 
Fig. 5.  Receptor tyrosine kinase activation in response to growth factor stimulation.  
(A) HDMEC, HCMEC, HBMEC and A2780 were grown to sub-confluence and treated with 
either VEGF-A or NRG-1 at 50 ng/ml for 10 minutes.  Intracellular signalling responses 
were analysed by Western blotting for phosphorylation of VEGFR-2, HER2 (EGFR-2), AKT 
and ERK1/2 using phospho-specific antibodies. Total protein was measured for VEGFR-2, 
HER2 and HER4.  Level of protein phosphorylation and protein levels are quantified 
relative to HDMEC basal level (B) Cells were treated with 50 ng/ml VEGF-A or 50 ng/ml 
NRG-1 for 72 hours. Cell proliferation was assessed by ATP Cell Titer Glo ATP assay.  
Data is presented as % of basal for each cell type, mean ± S.D., (n=3), * = p ≤ 0.05 
compared to basal, one way ANOVA, SPSS. (C) Cells were treated with 50 ng/ml NRG-1 
for 72 hours following pre-incubation with human IgG control (10 µg/ml) or Herceptin (10 
µg/ml). Data is presented as % of basal for each cell type, mean ± S.D., (n=3), * = p ≤ 0.05, 
one way ANOVA, SPSS.  
 
 
Fig. 6.  Doxorubicin viability in the presence and absence of Herceptin.  (A) HDMEC, 
HCMEC, HBMEC and A2780 cells were incubated with Herceptin at a range of 
concentrations for 72hrs and cell viability determined by Cell Titer Glo ATP assay. (B) 
Herceptin IC50s were generated.  (C) HDMEC, (D) HCMEC, (E) HBMEC and (F) A2780 
were treated with doxorubicin alone and in the presence of Herceptin (10 μg/ml) or a 
human IgG control (10 μg/ml). Cell viability was measured by Cell Titer Glo ATP assay. 
(G) IC50 levels were determined, mean ± S.D., (n=4).   






